As previously reported, Morgan Stanley analyst Dara Mohsenian downgraded Keurig Dr Pepper to Underweight from Equal Weight as he sees a negative risk-reward despite a "well telegraphed" Q1 earnings beat on strong pricing at heritage Dr. Pepper Snapple. Based on the firm's recent AlphaWise survey, the analyst sees risk to coffee growth, noting that his forecast of around 1.5% is below the market-implied 4% long-term coffee topline growth, which is a key driver of his EPS forecast by 2021 being 5% below consensus. Additionally, Keurig Dr Pepper shares trade at a premium to the average of beverage peers Coca-Cola (KO) and PepsiCo (PEP) despite lower expected long-term topline growth, Mohsenian noted. He cut his price target on Keurig Dr Pepper shares to $24 from $27.

JPMorgan lowered the firm's price target on Coca-Cola to $65 from $66 and keeps an Overweight rating on the shares ahead of the Q1 report. The analyst sees a favorable setup for 2024, but is more cautious on volumes in Q1 versus the Street and is not expecting a guidance raise.